Market Overview

UPDATE: Wedbush Raises PT to $13 on Sangamo BioSciences on HIV Progress, Time Value

Related SGMO
Dow Finishes Down 100+ Points For Second Consecutive Day
Dow Down 0.6%; CarMax Shares Fall After Q2 Results

Wedbush maintained Sangamo BioSciences (NASDAQ: SGMO) with an Outperform rating and raised the price target from $10.00 to $13.00.

Wedbush said, "Sangamo presented immunologic results supporting previous observations about the functionality and durability of SB-728-T modified T-cells at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). … We are reiterating our OUTPERFORM rating and increasing our fair value to $13 from $10 due to HIV progress, error correction, and time value. By focusing on CCR5 heterozygotes, we increased our peak penetration and net peak annual worldwide revenues to Sangamo to about $656 million from about $500 million."

Sangamo BioSciences closed at $10.26 on Wednesday.

Latest Ratings for SGMO

DateFirmActionFromTo
Sep 2014JefferiesInitiates Coverage onBuy
Aug 2014JP MorganInitiates Coverage onOverweight
Jun 2013Cowen & CompanyInitiates Coverage onOutperform

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (SGMO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters